Business Description
Addex Therapeutics is a Swiss drug discovery company founded in 2002 and headquartered in Geneva, focused on developing treatments for neurological conditions. Its most advanced drug candidate, Dipraglurant, is being studied for recovery after stroke or brain injury and for managing involuntary movements caused by Parkinson's disease medication. The company also has additional programs targeting pain, anxiety, addiction, chronic cough, and bladder problems. Addex works alongside major partners including Janssen Pharmaceuticals and Indivior to advance several of these treatments toward patients.
